跳至主要内容
临床试验/EUCTR2004-002399-40-DK
EUCTR2004-002399-40-DK进行中(未招募)不适用

Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial.

Rigshospitalet0 个研究点目标入组 530 人开始时间: 2005年3月22日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
530

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Inclusion criteria
  • *Cytologic / histologic diagnosis of stage IC-IV ovarian cancer
  • *Indication for chemotherapy treatment
  • *Age < 75 years.
  • *Life expectancy of at least 3 months
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Exclusion criteria
  • *Previous or concomitant malignant neoplasia (not including basocellular or
  • spinocellular skin carcinoma or in-situ carcinoma of the uterine cervix, provided
  • they are being adequately treated).
  • *Performance Status (ECOG) _ 3.
  • *Previous chemotherapy treatment
  • *Heart disease (heart failure, myocardial heart attack during the 6 months prior to
  • the trial, atrioventricular block of any degree, serious arrhythmia)
  • *Leukocytes < 4000/mm3, neutrophils < 2000/mm3, platelets < 100000/mm3
  • *Modifications of renal function (Creatininaemia _ 1.25 times the upper normal
  • limit) or liver function (SGOT or SGPT _ 1.25 times the upper normal limit)
  • *Present or suspected haemorrhagic syndromes
  • *Uncooperative and/or unreliable patients
  • *Patients' inability to access the centre due to area of residence
  • *Refusal of informed consent

研究者

相似试验